MissionIR Articles
Original content written and distributed as part of our ongoing relationships.
-
MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Oncology Expert Dr. Guy Travis Clifton as Chief Medical Officer
Calidi Biotherapeutics (NYSE American: CLDI) has named Dr. Guy Travis Clifton as Chief Medical Officer, Consultant and Advisor. The appointment comes as Calidi advances clinical development of CLD-201, a virotherapy for solid tumors, following a…
-
Newton Golf Company (NASDAQ: NWTG) Elevates Golf Performance with High-Quality Gravity Putters
In the game of golf, precision and consistency are essential, and nowhere is this more apparent than on the putting green. A well-made putter can mean the difference between shaving strokes off a round or…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Partners With Enpower Greentech to Produce Solid-State Batteries in California
Mullen Automotive (NASDAQ: MULN) has signed a Partnership and Supply Agreement with Enpower Greentech Inc. to manufacture and deliver SWIFT Series semi solid-state batteries (“SSB”) for use in commercial vehicles and various industrial applications. Production…
-
MissionIRNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (CSE: SUNN) Appoints Data Center Veteran as Advisor for Market Expansion
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (CSE: SUNN) has retained Jonathan Martone of Martone Advisors LLC to guide its planned expansion into the data center industry. Martone brings over 25 years of experience…
-
Strategic Moves and Innovation: How Massimo Group (NASDAQ: MAMO) Is Strengthening Its Market Position
Massimo (NASDAQ: MAMO) has been actively enhancing its market presence and operational efficiency through strategic partnerships and logistical expansions. These initiatives aim to strengthen the company’s position in the powersports and recreational vehicle industry. Strategic…
-
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research (https://ibn.fm/OpnDo). The report supports a $35…
-
MissionIRNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Driving Clean Energy Innovation Through Multiple Projects
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) is a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and…
-
Newton Golf Company (NASDAQ: NWTG) Is Focused on Fitted Golf Shafts, Committed to Advancing Players’ Performance
Golf is a sport that demands precision, consistency and control, where even the smallest adjustments in equipment can significantly impact performance. One of the most critical yet often overlooked components of a golf club is…
-
D-Wave Quantum Inc. (NYSE: QBTS) Introduces New Quantum Blockchain Architecture With Enhanced Security and Efficiency Over Classical Computing Approaches
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, has published a research paper introducing a new quantum blockchain architecture that could improve security and significantly reduce the electricity…
-
Massimo Group (NASDAQ: MAMO) Focuses on Key Partnerships, Committed to Offering Products to Broad Consumer Base
In today’s competitive business environment, robust retail partnerships are essential for companies aiming to expand their market reach and enhance brand visibility. Such collaborations enable businesses to leverage the strengths of their partners, ensuring products…
-
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Highlights U.S. Assembly and Tariff Exempt Status for EV Lineup
Mullen Automotive (NASDAQ: MULN) announced that its Mullen and Bollinger commercial electric vehicles are fully assembled in the United States and exempt from recently announced tariffs on vehicles and components. With 67% and 71% of…
-
Clene Inc. (NASDAQ: CLNN) to Share CNM-Au8(R) Progress at Jones Las Vegas Conference
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple…
-
MissionIRNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Surpasses 800 Advertisers, Maintains 243% CAGR Amid Rapid Expansion
Thumzup (NASDAQ: TZUP), a rising AdTech player in social media branding and programmatic marketing, announced it has exceeded 800 advertisers on its platform, with expectations to cross 1,000 by mid Q2 2025. The company reported…
-
SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Secures $7.3M Deal for Camillus Solar Project
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and…
-
MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position
CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference on April 9
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The…
-
MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds.…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Defeats Motion to Dismiss in Spoofing Lawsuit
Mullen Automotive (NASDAQ: MULN), an electric vehicle manufacturer, announced a key legal victory after a federal court denied a motion to dismiss its spoofing lawsuit against IMC Financial Markets, Clear Street Markets LLC, UBS Securities…
-
MissionIRNewsBreaks – GivBux Inc. (OTC: GBUX) Plans $212 Million Equity Sale Through Non-Dilutive Structure
GivBux (OTC: GBUX), a publicly traded Super App and charitable giving platform, announced plans to sell a 30% equity stake for $212 million through a non-dilutive transaction aimed at preserving shareholder value. Proceeds will be…
-
MissionIRNewsBreaks – Powered by Physics: Newton Golf Company’s (NASDAQ: NWTG) Rebrand Spotlights Game-Changing Technology
Newton Golf (NASDAQ: NWTG) has completed a strategic rebranding to emphasize its commitment to innovation and align more closely with its mission of integrating advanced physics principles into golf-equipment design. The restructuring was not merely a…
-
MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Option Agreement to Acquire Italian Biotech Pincell
Scinai Immunotherapeutics (NASDAQ: SCNI), announced it has signed a binding option agreement to acquire Pincell srl, an Italian biotech developing PC111, a first-in-class antibody targeting severe skin blistering disorders. In tandem, Scinai’s Polish subsidiary submitted…
-
Clene Inc.’s (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available for On-Demand Viewing
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and…
-
SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Expands Solar Portfolio with Two New Projects in Upstate New York
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and…
-
Company Share Purchase News Shows Optimism for Growing Social Media Tech Developer Thumzup Media Corp. (NASDAQ: TZUP)
Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) received a new pair of thumbs up votes recently when company insiders announced new open-market stock purchases of Thumzup shares, as well as ongoing share buyback…
-
D-Wave Quantum Inc. (NYSE: QBTS) Reports Strong Q4, 2024 Results with Increased Bookings and Cash Position
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, reported financial performance for the fourth quarter and full-year 2024, highlighting significant growth in bookings and a strengthened cash position.…
-
SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) CEO Richard Lu Discusses Company Mission, Near-Term Goals on Bell2Bell, Quick Charge Podcasts
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference
Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment…
-
Newton Golf Company (NASDAQ: NWTG) ‘Pioneering New Era’ in Growing Golf Equipment Market
The global golf equipment market is experiencing significant growth, driven by increasing participation and technological advancements. This upward trend presents substantial opportunities for companies operating within the golf-equipment sector, such as Newton Golf Company (NASDAQ: NWTG),…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) Unveils Progress on CNM-Au8(R), Eyes Potential Fast-Track FDA Approval
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple…
-
MissionIRNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the year…
-
Thumzup Media Corp. (NASDAQ: TZUP) Boosts Shareholder Value with Share Buyback
Social media branding and marketing innovator Thumzup (NASDAQ: TZUP) continues building, helping shareholders after its uplisting to the Nasdaq exchange, announcing recently that board members have approved a stock buyback program of up to $1 million in…
-
MissionIRNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Fuels Explosive Growth with Disruptive AdTech Platform
Thumzup (NASDAQ: TZUP) is leveraging its proprietary social media marketing platform, AdTech, which drives influencers to catapult the effectiveness of small-business advertising. Having achieved a growth rate of over 200% CAGR, Thumzup now serves more than…
-
Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and…
-
MissionIRNewsBreaks – Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial